Biomerica, Inc. (BMRA) |
|
0.8602 0.04 (4.9%)
|
09-29 15:58 |
|
Open: |
0.86 |
Pre. Close: |
0.82 |
|
High:
|
0.9 |
Low:
|
0.8201 |
|
Volume:
|
20,045 |
Market Cap:
|
14(M) |
|
|
|
Technical analysis |
as of: 2023-09-29 4:26:15 PM |
|
Short-term rate:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
|
Mid-term rate:
|
|
| Target: |
Six months: 1.33 One year: 1.56 |
| Support: |
Support1: 0.81 Support2: 0.68 |
| Resistance: |
Resistance1: 1.14 Resistance2: 1.34 |
| Pivot: |
1.02  |
| Moving Average: |
MA(5): 0.9 MA(20): 1.08
MA(100): 1.3 MA(250): 2.25 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 6.3 %D(3): 8.4 |
| RSI: |
RSI(14): 27.9  |
| 52-week: |
High: 5.25 Low: 0.81 |
| Average Vol(K): |
3-Month: 241 (K) 10-Days: 64 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BMRA ] has closed above bottom band by 7.1%. Bollinger Bands are 6.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.9 - 0.91 |
0.91 - 0.91 |
|
Low:
|
0.81 - 0.81 |
0.81 - 0.82 |
|
Close:
|
0.85 - 0.86 |
0.86 - 0.87 |
|
Company Description |
|
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California. |
Headline News |
Tue, 26 Sep 2023
Cantor Fitzgerald Analyst Reaffirms Neutral Rating and 4 Price ... - Best Stocks
Tue, 26 Sep 2023
Biomerica, Inc. (BMRA) Announces Dubai Government Grants ... - StreetInsider.com
Mon, 28 Aug 2023
Diagnostics Industry Leader Jack Kenny Joins Biomerica's - GlobeNewswire
Fri, 25 Aug 2023
Biomerica Reports Fiscal 2023 Year End Results - GlobeNewswire
Thu, 03 Aug 2023
CVS Health to Begin Nationwide In-Store Sales of Biomerica’s EZ Detect™ Colorectal Disease Screening Test - Yahoo Finance
Thu, 03 Aug 2023
Is Biomerica Inc (BMRA) Stock a Smart Investment Thursday? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Medical Devices |
| Shares Out. |
17 (M) |
| Shares Float |
16 (M) |
|
% Held by Insiders
|
7.2 (%) |
|
% Held by Institutions
|
33.1 (%) |
|
Shares Short
|
476 (K) |
|
Shares Short P.Month
|
345 (K) |
Stock Financials |
|
EPS
|
-0.47 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.69 |
|
Profit Margin (%)
|
-133.8 |
|
Operating Margin (%)
|
-129.9 |
|
Return on Assets (ttm)
|
-33.6 |
|
Return on Equity (ttm)
|
-71.3 |
|
Qtrly Rev. Growth
|
-79.1 |
|
Gross Profit (p.s.)
|
0.02 |
|
Sales Per Share
|
0.31 |
|
EBITDA (p.s.)
|
-0.41 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-5 (M) |
|
Levered Free Cash Flow
|
-2 (M) |
Stock Valuations |
|
PE Ratio
|
-1.83 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
1.22 |
|
Price to Sales
|
2.7 |
|
Price to Cash Flow
|
-2.64 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
